Therefore, identifying predictive biomarkers, such as KRAS mutation status [10], MATE1 expression levels [10,16], and emerging metabolic or immune-related patterns [13,15], is of paramount importance in moving toward personalized CRC management. Here, KRAS is linked to colorectal carcinoma.